Deep Brain Stimulation for Spinocerebellar Ataxia
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- People taking part
- 5 people, planned
- Started
- 27 Apr 2026
- Expected to end
- Mar 2031
- Type of study
- Interventional
- Treatments tested
- Deep Brain Stimulation (DBS)
- Record updated
- 13 July 2026
Who can take part
- Age
- 21 years to 89 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- A diagnosis of SCA6 by a Movement Disorders specialist following established criteria recommended by the Movement Disorders Society
- A positive genetic test for SCA6
- A total scale ≥ 8 on the Scale of the Assessment and Rating of Ataxia (SARA) rating scale
- Ability to walk with or without support (score < 8 on the 'gait' subsection of the SARA rating scale)
- Age ≥ 21 years and < 89 years
- Ability to give informed consent for the study
- Be able to understand the study protocol
Who cannot take part
- History of previously implanted neurostimulators, pacemakers, defibrillators, or metallic head implants
- Coagulopathy, uncontrolled epilepsy, or other medical condition considered to place the patient at elevated risk for surgical complications. Presence of a concomitant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis
- Requirement of diathermy, electroconvulsive therapy, or transcranial magnetic stimulation
- Severe cognitive impairment or dementia, defined as a score < 21 on the Montreal Cognitive Assessment (MoCA)
- Evidence of ataxia due to other etiologies, including but not limited to:; Genetic/inherited disorders other than SCA6; Acquired causes: tramautic brain injury, multiple sclerosis, paraneplastic cerebellar degeneration, infections or post-infectious cerebellitis, autoimmune ataxias (e.g., anti-GAD, gluten ataxia); Toxic/metabolic causes: alcoholic cerebellar degeneration, vitamin deficiencies; Structural, vascular, or neoplastic causes: cerebellar stroke, tumors, congenital malformations; Suspected multiple system atrophy-cerebellar type (MSA-C)
- The presence of active and untreated psychiatric illness, severe depression (Beck Depression Inventory ≥ 21), or personality disorder at the discretion of the study team
- Presence of a concominant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis
- Refractory Epilepsy
- Inability or unwillingness to comply with the study protocol
- Pregnancy or lactation
- Active suicidal ideation, defined as fined as a "Yes" response to questions #2-5 on the Columbia Suicide Severity Rating Scale, C-SSRS
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 21 and 89 years old?
This trial is currently available in United States.
- UCSF Weill Institute for NeurosciencesSan Francisco, United StatesContact: Marta San Luciano Palenzuela, MD, PhDTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Marta San Luciano Palenzuela, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to test the safety of placing Deep Brain Stimulators (DBS) in the cerebellum and using electrical stimulation of that part of the brain to treat symptoms related to the participants spinocerebellar ataxia. Five adults diagnosed with spinocerebellar ataxia type 6 (SCA6) with inadequate cerebellar symptom relief will be implanted with a Medtronic Percept Primary Cell Neurostimulator. The device will be implanted into the dentate nucleus, which is a structure located within the cerebellum that is responsible for controlling movement and balance.
Read full original descriptionShow less
Specifically, the investigators will be using adaptive deep brain stimulation (aDBS), which analyzes brain signals and automatically adjusts the strength, timing, and pattern of stimulation according to the patient's needs at any given moment. This study will evaluate the feasibility, safety, and tolerability of aDBS in SCA6 patients.
The group in the trial
- Adaptive Deep Brain Stimulation (aDBS)Treatment being tested
One month after patients undergo DBS surgery in the cerebellum, conventional deep brain stimulation (cDBS) programming will begin to identify stimulation parameters (such as amplitude, contact, frequency, and pulse width) and ensure no adverse wide effects are witness. This phase also allows the study team to make sure device and electrode placement are working as intended. About nine months after implantation, the investigators will switch system settings over to aDBS to evaluate the feasibility, safety, and tolerability in the dentate nucleus of the cerebellum. Symptoms and side effects will be assessed by patients' self-reports, validated clinical scales, and wearable devices, which will be used to track movements and sleep data.
Treatment: Deep Brain Stimulation (DBS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adaptive Deep Brain Stimulation Targeting the Dentate Nucleus to Treat Spinocerebellar Ataxia
- Criteria questions
- Built from NCT07288437, who can take part
- Record updated
- 13 July 2026